Indication
Mefamol® Oral suspension is indicated for treatment of the following:
- For the relief of mild to moderate pain including muscular or traumatic origin, headache, dental pain and post-operative pain.
- For the relief of pain associated with rheumatoid arthritis (including Still’s disease) and osteoarthritis.
- Mefamol® Oral suspension also used as an antipyretic.
Composition
Each 5ml contains :
- Mefenamic Acid 50 mg
Dosage
¤ Mefamol® Oral suspension is administrated after meals.
- Children (6 monthes-2 years): One teaspoonful (5ml);
- Children (2 years-5 years): Two teaspoonful (10ml);
- Children (5 years-9 years): Three teaspoonful (15ml);
- Children (9 years-12 years): Four teaspoonful (20ml);To be taken three times a day or as directed.
- It is recommended that it should not be given for longer than 7 days to children unless they are receiving mefenamic acid for juvenile chronic arthritis (Still’s disease).
- The active substance in Mefamol® Oral suspension is Mefenamic Acid that is a non-steroidal anti-inflammatory drug (NSAIDs) that exhibits anti-inflammatory, analgesic and antipyretic activities.
Each 5ml contains :
- Mefenamic Acid 50 mg
Mefamol® Oral suspension is indicated for treatment of the following:
- For the relief of mild to moderate pain including muscular or traumatic origin, headache, dental pain and post-operative pain.
- For the relief of pain associated with rheumatoid arthritis (including Still’s disease) and osteoarthritis.
- Mefamol® Oral suspension also used as an antipyretic.
Mefamol® Oral suspension is contraindicated in the following cases:
- Patients with hypersensitivity to Mefenamic Acid or patients in whom aspirin or other Non-steroidal anti-inflammatory drugs precipitate symptoms of bronchospasm, allergic rhinitis or urticaria.
- Patients with inflammatory bowel disease, and peptic ulceration.
- Patients with renal or hepatic impairment.
- Patients with Porphyria.
- Mefenamic Acid may enhance of the effects of oral anticoagulants and increase plasma concentrations of lithium, methotrexate, and cardiac glycosides.
- It may interact with hydantoins.
- Diarrhea and rashes.
- Drowsiness and dizziness.
- Effects on the blood including thrombocytopenia, occasionally haemolytic anaemia, and rarely aplastic anaemia.
Overdose:
- Mefenamic acid overdose has been associated with CNS toxicity, especially with convulsions, which if prolonged or recurrent require treatment. Coma has also been reported.
¤ Mefamol® Oral suspension is administrated after meals.
- Children (6 monthes-2 years): One teaspoonful (5ml);
- Children (2 years-5 years): Two teaspoonful (10ml);
- Children (5 years-9 years): Three teaspoonful (15ml);
- Children (9 years-12 years): Four teaspoonful (20ml);To be taken three times a day or as directed.
- It is recommended that it should not be given for longer than 7 days to children unless they are receiving mefenamic acid for juvenile chronic arthritis (Still’s disease).
- Apart from Still’s disease, therapy should not be continued for longer than 7 days in children.
- Treatment should be discontinued if diarrhea and rashes occur.
- It should be taken with precaution in pregnancy and during breast feeding.
- Bottle of 60 ml Oral Suspension .
- Store in a dry place at temperature not exceeding 25°C.
- Protect from direct sunlight.